Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -4,249.23%.

  • Insight Molecular Diagnostics' EBITDA Margin rose 750294.00% to -4,249.23% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,392.91%, marking a year-over-year increase of 475561.00%. This contributed to the annual value of -3,245.14% for FY2024, which is 157275.00% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' EBITDA Margin is -4,249.23%, which was down 123.64% from -1,900.00% recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year EBITDA Margin high stood at 1,969.70% for Q1 2023, and its period low was -11,752.17% during Q3 2024.
  • Over the past 3 years, Insight Molecular Diagnostics' median EBITDA Margin value was -2,262.92% (recorded in 2024), while the average stood at -3,335.81%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 5,168,307bps in 2021, then plummeted by 1,023,399bps in 2024.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' EBITDA Margin stood at -994.15% in 2021, then plummeted by 325,695bps to -4,251.09% in 2022, then tumbled by 90,145bps to -5,152.55% in 2023, then skyrocketed by 288,963bps to -2,262.92% in 2024, then soared by 750,294bps to -4,249.23% in 2025.
  • Its last three reported values are -4,249.23% in Q3 2025, -1,900.00% for Q2 2025, and -318.01% during Q1 2025.